This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Xolair
  • /
  • A Phase III Study of Efficacy and Safety of Ligeli...
Clinical trial

A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Read time: 3 mins
Last updated:20th Oct 2018
Identifier: NCT03580356

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.

The study population will consist of approximately 1050 male and female subjects aged ≥ 12 years who have been diagnosed with CSU and who remain symptomatic despite the use of H1-antihistamines. Of these, approximately 1000 adults and 50 adolescents are planned for inclusion in the study.

This is a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 1050 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: This is a Phase III multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Patients, investigator staff and personnel performing the study assessments will remain blinded to the identity of the treatment from the time of randomization until final database lock. The study drug must be prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded study drug administrator. Neither the unblinded pharmacist nor the unblinded study drug administrator will be involved in any assessments.
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Actual Study Start Date: October 20, 2018
Estimated Primary Completion Date: May 4, 2020
Estimated Study Completion Date: April 30, 2021

Arms:
- Experimental:
Ligelizumab Dose A
- Experimental: Ligelizumab Dose B
- Experimental: Ligelizumab Dose B
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-01-31
Study type(s) Interventional
Expected enrolment 1050
Study start date 2018-10-20
Estimated primary completion date 2020-05-04

View full details